SPRB实时信号 | 通过Getagraph.com最大化利润

出售 112929 min ago

@ $4.51

发出时间: 14 Feb 2024 @ 04:35

回报率: -84.09%

上一信号: Feb 13 - 22:31

上一信号: 购买

回报率: 4.64 %

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

Stats
今日成交量	747 686
平均成交量	1.38M
市值	29.52M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.00300 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Novo Holdings A/s	Sell	465 021	COMMON STOCK
2024-03-18	Novo Holdings A/s	Sell	842 020	COMMON STOCK
2024-03-19	Novo Holdings A/s	Sell	593 000	COMMON STOCK
2024-03-20	Novo Holdings A/s	Sell	359 979	COMMON STOCK
2024-03-14	Novo Holdings A/s	Sell	1 912 316	COMMON STOCK

INSIDER POWER
2.52
Last 98 transactions
Buy: 11 294 782 \| Sell: 4 967 660

音量相关性

長: 0.08 (neutral)

短: 0.26 (neutral)

Signal:(43.972) Neutral

Spruce Biosciences, Inc. 相关性

10 最正相关
DYNT	0.967
DGLY	0.954
FTFT	0.94
SLNO	0.94
SYKE	0.929
CVV	0.927
LIVE	0.925
CSWI	0.923
FELE	0.922
IPHA	0.921

10 最负相关
MTEX	-0.906
LCAP	-0.905
AHPI	-0.899
NAKD	-0.887
PROC	-0.883
LAWS	-0.88
VERA	-0.872
GRPH	-0.869
OP	-0.868
TRIT	-0.868

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Spruce Biosciences, Inc. 相关性 - 货币/商品

-0.46
( neutral )

-0.39
( neutral )

0.00
( neutral )

0.51
( weak )

Spruce Biosciences, Inc. 财务报表

Annual	2023
营收:	$10.09M
毛利润:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2023
营收:	$10.09M
毛利润:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2022
营收:	$0
毛利润:	$-429 000 (0.00 %)
EPS:	$-1.920

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.813

Financial Reports:

No articles found.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.